A detailed history of New Edge Advisors, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 1,505 shares of EDIT stock, worth $1,971. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,505
Previous 1,555 3.22%
Holding current value
$1,971
Previous $7,000 28.57%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.39 - $5.96 $169 - $298
-50 Reduced 3.22%
1,505 $5,000
Q2 2024

Aug 15, 2024

SELL
$4.67 - $7.28 $1,517 - $2,366
-325 Reduced 17.29%
1,555 $7,000
Q3 2023

Nov 14, 2023

SELL
$6.92 - $9.31 $2,076 - $2,793
-300 Reduced 13.76%
1,880 $14,000
Q2 2023

Aug 14, 2023

SELL
$6.36 - $11.47 $508 - $917
-80 Reduced 3.54%
2,180 $17,000
Q1 2023

May 12, 2023

SELL
$7.03 - $11.53 $3,388 - $5,557
-482 Reduced 17.58%
2,260 $16,000
Q4 2022

Feb 14, 2023

BUY
$8.32 - $13.21 $22,813 - $36,221
2,742 New
2,742 $24,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.